Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/epizyme-inc-epzm-financial-n-strategic-swot-analysis-review_en.gif)
Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Epizyme Inc (Epizyme) discovers, develops and markets novel epigenetic therapies for the treatment of cancer and other disorders. The company’s marketed product includes, Tazverik (tazemetostat) is an oral, first-in-class, small molecule inhibitor of the EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. It pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.
Epizyme Inc Key Recent Developments
May 06,2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 29,2021: Epizyme Announces Date of First Quarter 2021 Financial Results
Mar 02,2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
Feb 23,2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
Feb 16,2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Epizyme Inc (Epizyme) discovers, develops and markets novel epigenetic therapies for the treatment of cancer and other disorders. The company’s marketed product includes, Tazverik (tazemetostat) is an oral, first-in-class, small molecule inhibitor of the EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. It pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.
Epizyme Inc Key Recent Developments
May 06,2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 29,2021: Epizyme Announces Date of First Quarter 2021 Financial Results
Mar 02,2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
Feb 23,2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
Feb 16,2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Epizyme Inc - Key Facts
Epizyme Inc - Key Employees
Epizyme Inc - Key Employee Biographies
Epizyme Inc - Major Products and Services
Epizyme Inc - History
Epizyme Inc - Company Statement
Epizyme Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Epizyme Inc - Business Description
Other Break-up: Collaboration Revenue
Performance
Other Break-up: Product Revenue
Performance
R&D Overview
Epizyme Inc - Corporate Strategy
Epizyme Inc - SWOT Analysis
SWOT Analysis - Overview
Epizyme Inc - Strengths
Epizyme Inc - Weaknesses
Epizyme Inc - Opportunities
Epizyme Inc - Threats
Epizyme Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Epizyme Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 29, 2021: Epizyme Announces Date of First Quarter 2021 Financial Results
Mar 02, 2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
Feb 23, 2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Nov 06, 2020: Epizyme reports business progress and third quarter 2020 financial results
Aug 04, 2020: Epizyme reports business progress and second quarter 2020 financial results
May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results
Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Epizyme Inc - Key Facts
Epizyme Inc - Key Employees
Epizyme Inc - Key Employee Biographies
Epizyme Inc - Major Products and Services
Epizyme Inc - History
Epizyme Inc - Company Statement
Epizyme Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Epizyme Inc - Business Description
Other Break-up: Collaboration Revenue
Performance
Other Break-up: Product Revenue
Performance
R&D Overview
Epizyme Inc - Corporate Strategy
Epizyme Inc - SWOT Analysis
SWOT Analysis - Overview
Epizyme Inc - Strengths
Epizyme Inc - Weaknesses
Epizyme Inc - Opportunities
Epizyme Inc - Threats
Epizyme Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Epizyme Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 06, 2021: Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
Apr 29, 2021: Epizyme Announces Date of First Quarter 2021 Financial Results
Mar 02, 2021: Epizyme outlines clinical progress, TAZVERIK development strategy and pipeline priorities during company’s strategic vision call
Feb 23, 2021: Epizyme provides business update and reports fourth quarter and full year 2020 financial results
Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Feb 16, 2021: Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Nov 06, 2020: Epizyme reports business progress and third quarter 2020 financial results
Aug 04, 2020: Epizyme reports business progress and second quarter 2020 financial results
May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results
Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Epizyme Inc, Key Facts
Epizyme Inc, Key Employees
Epizyme Inc, Key Employee Biographies
Epizyme Inc, Major Products and Services
Epizyme Inc, History
Epizyme Inc, Subsidiaries
Epizyme Inc, Key Competitors
Epizyme Inc, Ratios based on current share price
Epizyme Inc, Annual Ratios
Epizyme Inc, Annual Ratios (Cont...1)
Epizyme Inc, Interim Ratios
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Epizyme Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Epizyme Inc, Key Facts
Epizyme Inc, Key Employees
Epizyme Inc, Key Employee Biographies
Epizyme Inc, Major Products and Services
Epizyme Inc, History
Epizyme Inc, Subsidiaries
Epizyme Inc, Key Competitors
Epizyme Inc, Ratios based on current share price
Epizyme Inc, Annual Ratios
Epizyme Inc, Annual Ratios (Cont...1)
Epizyme Inc, Interim Ratios
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Epizyme Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Epizyme Inc, Performance Chart (2016 - 2020)
Epizyme Inc, Ratio Charts
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Epizyme Inc, Performance Chart (2016 - 2020)
Epizyme Inc, Ratio Charts
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021